[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cel...
Source: Roche Investor Update - April 25, 2022 Category: Pharmaceuticals Source Type: news

Avacopan Shows Efficacy Signal for Rare Kidney Disease, C3G Avacopan Shows Efficacy Signal for Rare Kidney Disease, C3G
Avacopan, recently FDA approved for ANCA-associated vasculitis, showed significant benefit for reducing disease chronicity in a randomized trial of 52 patients with C3 glomerulopathy.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 7, 2022 Category: Allergy & Immunology Tags: Nephrology News Source Type: news

EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis
The recommendations advise on managing cardiovascular health in patients with gout, vasculitis, systemic sclerosis, myositis, Sj ögren syndrome, lupus, antiphospholipid syndrome, and other diseases.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 24, 2022 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

New two-year data for Roche ’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss
This study will evaluate the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in participants with diabetic macular edema compared with intravitreal ranibizumab (Pagoda) [Internet; cited January 2022]. Available from:https://clinicaltrials.gov/ct2/show/NCT04108156.[14] ClinicalTrials.gov. A multicenter, randomized study in participants with diabetic retinopathy without center-involved diabetic macular edema to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered via the port delivery system relative to the comparator arm (PAVILION) [Internet; cited January 2022]. A...
Source: Roche Media News - February 11, 2022 Category: Pharmaceuticals Source Type: news

New two-year data for Roche ’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss
This study will evaluate the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in participants with diabetic macular edema compared with intravitreal ranibizumab (Pagoda) [Internet; cited January 2022]. Available from:https://clinicaltrials.gov/ct2/show/NCT04108156.[14] ClinicalTrials.gov. A multicenter, randomized study in participants with diabetic retinopathy without center-involved diabetic macular edema to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered via the port delivery system relative to the comparator arm (PAVILION) [Internet; cited January 2022]. A...
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news

What are the Main Differences Between MIS-C and Kawasaki Disease?
Discussion SARS-CoV-2 or COVID-19 was first observed in Wuhan China in late 2019. By March 2020 it had spread to become a world-wide pandemic and continues today despite vaccination and other public health measures. Early on people were worried that children would be the major age group affected, but the major groups were older individuals and those with underlying health problems. That is not to say that children are not affected as they were and could have severe disease. However as an overall group, they tend to get the virus and have less severe symptoms than adults. Severe disease is about 1% of pediatric cases compar...
Source: PediatricEducation.org - November 22, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

ADVOCATE: Avacopan Shows Renal Benefits in ANCA Vasculitis ADVOCATE: Avacopan Shows Renal Benefits in ANCA Vasculitis
The oral C5a receptor inhibitor could allow for the ' previously unthinkable ' avoidance of steroid treatment, and related adverse effects, in those with ANCA-associated vasculitis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2021 Category: Consumer Health News Tags: Nephrology News Source Type: news

FDA approves add-on drug for adults with rare form of blood vessel inflammation
FDA has approved Tavneos (avacopan) as an add-on treatment to standard therapy including glucocorticoids for adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Tavneos helps to reduce blood vessel inflammation and offers patients an additional t (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 13, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Nephrotic Syndrome and Vasculitis After SARS-CoV-2 Vaccine Nephrotic Syndrome and Vasculitis After SARS-CoV-2 Vaccine
Are reported cases of nephrotic syndrome and vasculitis associated with the administration of the COVID-19 vaccine?Nephrology Dialysis Transplantation (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 17, 2021 Category: Intensive Care Tags: Nephrology Journal Article Source Type: news

What Are the Advantages and Disadvantages of Different Renal Replacement Therapies?
Discussion Kidneys are amazing in that they filter the blood, eliminate toxins, balance fluids and electrolytes plus have a lot of reserve to do the job they need to do even when injured. Therefore, depending on the problem, chronic renal disease (CRD) often allows time before renal replacement therapy (RRT) is needed. RRT currently is dialysis (peritoneal or hemodialysis) or renal transplant. In general, the patient’s own kidneys do the best job for them but there is always a balance between the problems of CRD and its management, versus the potentially improved renal function with RRT. RRT itself though has a diffe...
Source: PediatricEducation.org - September 13, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

How Do You Treat Immersion Foot Injury?
Discussion All occupations have some type of potential health consequences. Some are obvious because of the environment such as kitchen workers, first responders, helicopter pilots, etc. Others are may be less obvious or not considered such as slip and falls, cleaning supply chemical exposure, animal bites for postal and utility workers, etc. Noise and lifting objects are often overlooked problems in some settings but obvious in others such as construction. Protective measures, especially appropriate education and training and protective clothing and safety gear are obviously important for performing the work as safely as ...
Source: PediatricEducation.org - July 26, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Three New Drugs Implicated in ANCA-Associated Vasculitis Three New Drugs Implicated in ANCA-Associated Vasculitis
Mirabegron, sofosbuvir, and nintedanib join a list of 12 other drugs that have been linked to an overreporting of drug-associated ANCA vasculitis.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 16, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

New ACR Guidelines Give Advice on Six Forms of Vasculitis New ACR Guidelines Give Advice on Six Forms of Vasculitis
Nearly all recommendations made for giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, and three forms of ANCA-associated vasculitis are conditional rather than strong.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 16, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news